PH12015500282B1 - N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug - Google Patents
N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug Download PDFInfo
- Publication number
- PH12015500282B1 PH12015500282B1 PH12015500282A PH12015500282A PH12015500282B1 PH 12015500282 B1 PH12015500282 B1 PH 12015500282B1 PH 12015500282 A PH12015500282 A PH 12015500282A PH 12015500282 A PH12015500282 A PH 12015500282A PH 12015500282 B1 PH12015500282 B1 PH 12015500282B1
- Authority
- PH
- Philippines
- Prior art keywords
- mmol
- acetohydrazide
- indol
- compound
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120095729 | 2012-08-30 | ||
| KR20120108972 | 2012-09-28 | ||
| PCT/KR2013/007751 WO2014035149A1 (en) | 2012-08-30 | 2013-08-29 | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015500282A1 PH12015500282A1 (en) | 2015-04-27 |
| PH12015500282B1 true PH12015500282B1 (en) | 2015-04-27 |
Family
ID=50183887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015500282A PH12015500282B1 (en) | 2012-08-30 | 2015-02-09 | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9447083B2 (enExample) |
| EP (1) | EP2890677B1 (enExample) |
| JP (1) | JP6139682B2 (enExample) |
| KR (1) | KR101561987B1 (enExample) |
| CN (1) | CN104755460B (enExample) |
| AU (1) | AU2013309723B2 (enExample) |
| BR (1) | BR112015004432A2 (enExample) |
| CA (1) | CA2881797C (enExample) |
| ES (1) | ES2651312T3 (enExample) |
| IN (1) | IN2015MN00411A (enExample) |
| MX (1) | MX368381B (enExample) |
| NZ (1) | NZ704807A (enExample) |
| PH (1) | PH12015500282B1 (enExample) |
| RU (1) | RU2622651C2 (enExample) |
| WO (1) | WO2014035149A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106986789B (zh) * | 2016-01-20 | 2019-07-16 | 中国人民解放军军事医学科学院生物医学分析中心 | 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用 |
| CA3114565A1 (en) * | 2018-09-28 | 2020-04-02 | Nissan Chemical Corporation | Additive for medium for promoting production of paracrine factor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| DE102004037515A1 (de) | 2003-08-22 | 2005-03-17 | Merck Patent Gmbh | Verfahren zur Herstellung von Aldehyden |
| WO2006121684A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International, Gmbh | Acyl hydrazones for treating cardiovascular diseases |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009155362A1 (en) | 2008-06-19 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Small molecule hematopoietic growth factor mimetic compounds and their uses |
| WO2013032907A1 (en) | 2011-08-26 | 2013-03-07 | The Broad Institute, Inc. | Compounds and methods for the treatment of cancer stem cells |
-
2013
- 2013-08-29 MX MX2015002601A patent/MX368381B/es active IP Right Grant
- 2013-08-29 CN CN201380056385.7A patent/CN104755460B/zh not_active Expired - Fee Related
- 2013-08-29 BR BR112015004432A patent/BR112015004432A2/pt not_active Application Discontinuation
- 2013-08-29 ES ES13833207.7T patent/ES2651312T3/es active Active
- 2013-08-29 EP EP13833207.7A patent/EP2890677B1/en not_active Not-in-force
- 2013-08-29 IN IN411MUN2015 patent/IN2015MN00411A/en unknown
- 2013-08-29 RU RU2015105511A patent/RU2622651C2/ru active
- 2013-08-29 JP JP2015529676A patent/JP6139682B2/ja not_active Expired - Fee Related
- 2013-08-29 CA CA2881797A patent/CA2881797C/en not_active Expired - Fee Related
- 2013-08-29 WO PCT/KR2013/007751 patent/WO2014035149A1/en not_active Ceased
- 2013-08-29 AU AU2013309723A patent/AU2013309723B2/en not_active Ceased
- 2013-08-29 NZ NZ704807A patent/NZ704807A/en not_active IP Right Cessation
- 2013-08-29 US US14/424,749 patent/US9447083B2/en not_active Expired - Fee Related
- 2013-08-30 KR KR1020130103747A patent/KR101561987B1/ko not_active Expired - Fee Related
-
2015
- 2015-02-09 PH PH12015500282A patent/PH12015500282B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014035149A1 (en) | 2014-03-06 |
| KR101561987B1 (ko) | 2015-10-20 |
| MX368381B (es) | 2019-09-30 |
| AU2013309723B2 (en) | 2016-07-14 |
| RU2015105511A (ru) | 2016-10-20 |
| CA2881797C (en) | 2017-08-01 |
| EP2890677A1 (en) | 2015-07-08 |
| NZ704807A (en) | 2016-06-24 |
| US9447083B2 (en) | 2016-09-20 |
| US20150252030A1 (en) | 2015-09-10 |
| CN104755460A (zh) | 2015-07-01 |
| CN104755460B (zh) | 2017-05-10 |
| EP2890677A4 (en) | 2016-03-09 |
| AU2013309723A1 (en) | 2015-02-26 |
| CA2881797A1 (en) | 2014-03-06 |
| PH12015500282A1 (en) | 2015-04-27 |
| BR112015004432A2 (pt) | 2017-07-04 |
| JP2015526508A (ja) | 2015-09-10 |
| KR20140029318A (ko) | 2014-03-10 |
| JP6139682B2 (ja) | 2017-05-31 |
| EP2890677B1 (en) | 2017-11-15 |
| RU2622651C2 (ru) | 2017-06-19 |
| ES2651312T3 (es) | 2018-01-25 |
| IN2015MN00411A (enExample) | 2015-09-04 |
| MX2015002601A (es) | 2015-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6238980B2 (ja) | 補体経路モジュレーターおよびその使用 | |
| US6028085A (en) | Indole derivatives as 5-HT receptor antagonist | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| US8580817B2 (en) | 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | |
| KR20200118062A (ko) | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 | |
| WO2016041489A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| JP2016535042A (ja) | ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 | |
| KR20180123586A (ko) | 피리미딘 유도체의 제조 방법 | |
| CN104169254A (zh) | 作为n-甲酰肽样受体-1(fprl-1)受体的调节剂的芳基脲衍生物 | |
| HRP980357A2 (en) | Bis-indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| JP6831324B2 (ja) | 特定のタンパク質キナーゼ阻害剤 | |
| KR100549631B1 (ko) | 시아노구아니딘, 이의 제조방법 및 이를 함유하는 약제학적 제제 | |
| EP2890677B1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug | |
| CN111372936B (zh) | Mcl-1选择性抑制剂及其制备和用途 | |
| RU2248969C2 (ru) | Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и противораковый агент | |
| EP2141166A1 (en) | Adenine receptor ligands | |
| EP2970239A1 (en) | Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators | |
| JP2018523660A (ja) | ベンゾジアゼピン誘導体の合成 | |
| KR20220132811A (ko) | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 | |
| CN108863948A (zh) | 嘧啶取代的酰肼衍生物及其用途 | |
| CN108863914A (zh) | 吡啶取代的酰肼衍生物及其用途 |